Claims for Patent: 8,524,746

Summary for Patent: 8,524,746

Title:	Dosage regimen for COMT inhibitors
Abstract:	The invention relates to the use of an oxodiazolyl compound (I) for the preparation of a medicament for the prevention or treatment of central and peripheral nervous system associated disorders, wherein said medicament is administered according to a dosing regimen having a dosing periodicity ranging from about twice a day to about once every other day. ##STR00001##
Inventor(s):	Learmonth; David Alexander (S. Mamede do Coronado, PT), Kiss; Laszlo Erno (S. Mamede do Coronado, PT), Palma; Pedro Nuno Leal (S. Mamede do Coronado, PT), Ferreira; Humberto dos Santos (S. Mamede do Coronado, PT), Silva; Patricio Manuel Vieira Araujo Soares da (S. Mamede do Coronado, PT)
Assignee:	Bial-Portela & Ca., S.A. (S. Mamede do Coronado, PT)
Application Number:	12/524,848
Patent Claims:	1. Method of treating a movement disorder in a patient in need thereof comprising administering to the patient about twice every day to about once every other day a pharmacologically effective dose of 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl- ]-3-nitrobenzene-1,2-diol or a pharmacologically acceptable salt thereof, wherein the movement disorder is selected from Parkinson's disease, dystonia, dyskinesia, and extrapyrimidal syndromes. 2. Method as claimed in claim 1 wherein the administration is once daily. 3. Method as claimed in claim 1 wherein the administration is twice daily. 4. Method as claimed in claim 1 wherein the administration is once every other day. 5. Method according to claim 1, wherein the movement disorder is treatable by L-DOPA and/or AADC therapy. 6. Method as claimed in claim 1 wherein the movement disorder is Parkinson's disease. 7. Method according to claim 1 wherein the method further comprises the step of administering L-DOPA to the patient. 8. Method according to claim 1 wherein the method further comprises the step of administering an AADC inhibitor to the patient. 9. Method according to claim 1 wherein the patient is receiving therapy with L-DOPA or an AADC inhibitor or both L-DOPA and an AADC inhibitor. 10. Method according to claim 1 wherein the method further comprises the step of administering of L-DOPA and an AADC inhibitor to the patient either concomitantly or sequentially with the compound as defined in claim 1. 11. Method according to claim 1 wherein the method further comprises the step of administering of L-DOPA and an AADC inhibitor to the patient separately with the compound as defined in claim 1. 12. Method according to claim 1 wherein the effective daily doses of compounds of formula I are in the range of 1 to 1000 mg/day. 13. Method according to claim 1 wherein the effective daily doses of compounds of formula I are in the range of 2 to 500 mg/day. 14. Method according to claim 1 wherein the effective daily doses of compounds of formula I are in the range of 3 to 250 mg/day. 15. Method according to claim 1 wherein the effective daily doses of compounds of formula I are in the range of 5 to 100 mg/day. 16. Method according to claim 1 wherein the administration is in the morning, mid-day, noon, afternoon, evening, or midnight. 17. Method according to claim 1 wherein the administration is in the evening.